Troy Monthye Co-Founder and CEO

Troy is the CEO and co-founder of ModoSpira. Influenced by two separate, personal interactions with people living with COPD, Troy was moved by how little had apparently changed in the 15 years separating those encounters, particularly in the mindsets of those patients and how they approached their condition…through inaction and resignation. Troy founded ModoSpira to reorient people diagnosed with COPD to the fact that they live with a very treatable condition, and to provide those people with all of the knowledge and tools to improve their symptoms and quality of life. Troy assembled the brightest minds, kindest hearts, and most inspiring souls, to finally offer people living with COPD a clinically proven, customizable, affordable, and sustainable solution for their treatment of COPD.

Ravi Kalhan, MD, MS Co-founder and Chief Medical Officer

Ravi is the co-founder and CMO of ModoSpira, after having devoted his entire career to the advancement of treatment and research in COPD. Ravi is Director of the Northwestern University Asthma and COPD Program, and medical director of the pulmonary rehabilitation program at the Rehabilitation Institute of Chicago, the nation's top rehabilitation hospital. In these positions, Ravi manages the care for thousands of patients with COPD and other chronic conditions. These experiences have formed the basis for what ModoSpira provides to patients…evidence-based therapies proven to engage patients and improve their symptoms and self-efficacy.

Ravi attended college at Brown University in Providence, RI where he majored in modern American history. He subsequently entered medical school at Case Western Reserve University School of Medicine and completed his internal medicine residency at the Hospital of the University of Pennsylvania. He then moved to Chicago where he pursued his fellowship training in Pulmonary and Critical Care Medicine at Northwestern Memorial Hospital, and has been on the Northwestern University Feinberg School of Medicine faculty since 2006. His research interests relate to respiratory epidemiology, in particular identification of early risk factors that impact the vulnerability of certain cigarette smokers to develop COPD. He is also involved in clinical trials of new therapies for both asthma and COPD. He additionally serves as Chairman of the Illinois COPD Coalition, a multidisciplinary group including representatives from community-based organizations, public health departments, professional organizations, patients, caregivers, healthcare providers, pharmaceutical companies and home healthcare providers which has the goal of implementing sustainable solutions for reducing the burden of COPD in Illinois. Ravi serves on the Board of Directors of the Respiratory Health Association, the Medical and Scientific Advisory Committee of the COPD Foundation, is an associate editor for Annals of the American Thoracic Society, and on the editorial boards of the American Journal of Respiratory and Critical Care Medicine and Thorax.

Michael Skolnik VP of Business Development

Michael Skolnik leads the business development efforts for ModoSpira and has a deep commitment to easing the burdens of COPD and lung disease, having lost a family member to COPD and with other family members suffering from lung disease. Michael believes that ModoSpira provides the opportunity for all people living with COPD to better their condition and live a more normal life with less fear of exacerbation. He also understands the economic impact of COPD in his role as Managing Consultant with the Value Based Health Care Institute. The VBHCI is instrumental in developing and contracting effective managed care networks, recommending and implementing value based incentive models, collaborating with partners in implementing population health programs, and helping ACOs and Self-Funded Employer plans operationalize and go to market.

Michael brings two decades of experience designing and commercializing innovative commercial, Medicare and Managed Care solutions that empower providers and consumers to take a more active role in their health. Michael recently completed the contracting of a 4500-provider health plan for Canopy Health in the San Francisco Bay Area. Prior to joining the VBHCI, Michael served as chief executive officer for Sutter Health's Managed Care Systems and Director of Network Development and Management for Blue Cross and Blue Shield of MA. Michael believes that for change to occur within the health care system that there has to be a focus on tightly managing the care for the 17% chronic care patients who account for over 72% of the health care dollars spent in the United States. Michael earned a MS degree in Health Care and Business Administration from Trinity University.

Marisa Alcaro, DPT VP of Intervention

If you’re one of our patients perspiring while performing one of our demanding physiotherapy regimens, you have Marisa to blame. But if you’re one of our expert patient graduates, thankful for improved symptoms and a renewed outlook on life, well, you also have Marisa to thank. Marisa knows how to produce positive results in patients’ symptoms and outlooks – she does it every day, providing pulmonary rehabilitation therapy at the nation’s top-rated facility. Marisa earned a Doctor in Physical Therapy degree from Northwestern University, and remains on their clinical faculty teaching graduate students about cardiovascular and pulmonary dysfunction and rehabilitation.

Tamara Muller Chairman

Tami has been keeping respiratory patients stable and healthy at home for almost 30 years as owner and operator of one of the Midwest’s premiere high-acuity, respiratory-oriented skilled nursing agencies. Tami’s multi-disciplinary approach was defining post-acute care coordination before the term was popular, and she has designed some of the most innovative home-based respiratory programs in the country. Though the clinical aspects of Modo Spira’s intervention were conceived and designed by our board-certified pulmonologist, the way in which the intervention touches the patients’ lives is based largely on the three decades of experience Tami has with delivering complex care to patients in the comfort and safety of their own homes.

Medical Advisory Board

Mark T. Dransfield, MD

Mark Dransfield completed his MD degree at the University of North Carolina at Chapel Hill followed by residency in internal medicine and fellowship in pulmonary and critical care at the University of Alabama at Birmingham where he served as chief fellow. He has been on the faculty at UAB since 2003 and is currently Associate Professor of Medicine in the Division of Pulmonary, Allergy and Critical Care and also a staff physician at the Birmingham VA Medical Center. He serves as the Medical Director of the UAB Lung Health Center and the Medical Director of Pulmonary Rehabilitation. He was named Top 10 Teacher in the Department of Medicine in 2006-2008 and in 2009 was a recipient of the Cobbs-Rutsky Award for Clinical Excellence. He has been named one of America’s Best Doctors in 2010-2014. He has served on the ATS Clinical Problems Assembly Program Committee since 2008 and is also a member of the guideline development committee for the American College of Chest Physicians and Canadian Thoracic Society Evidence-based Guidelines for the Prevention of Acute Exacerbations.

Dr. Dransfield’s primary clinical and research interest is chronic obstructive pulmonary disease (COPD). He has particular interest in the care of patients with advanced COPD and directs the UAB lung volume reduction surgery evaluation process and the UAB/Centers for Medicare and Medicaid COPD Integrated Practice Unit. He is Principal Investigator for multiple clinical trials at the UAB Lung Health Center (LHC) including the NIH sponsored COPD Clinical Research Network studies, COPDGene, and Spiromics as well as numerous phase II-IV pharma sponsored projects. As Medical Director of the LHC he also oversees multiple translational research projects focusing on airways disease. The LHC encompasses approximately 11,300 square feet of laboratory and clinical research space. The LHC is currently conducting more than 20 clinical trials in COPD and asthma and houses cores in Human Pulmonary Function, Recruitment, and Regulatory Support as well as a Biospecimen Repository and has collaborations on campus for the performance of research bronchoscopy, proteomics, synthetic chemistry, and murine pulmonary function testing and specimen analysis. He has published over 80 research papers focusing on COPD related epidemiology, co-morbid illness, pathophysiology and therapeutics.

MeiLan Han, MD, MS

MeiLan Han is an Associate Professor of Medicine in the Division of Pulmonary and Critical Care at the University of Michigan. Dr. Han received her medical degree from the University of Washington in Seattle, WA. She completed her residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine at the University of Michigan. Dr. Han has also completed a Master's Degree program in Biostatistics and Clinical Study Design at the University of Michigan School of Public Health. She is co-chair of the University of Michigan COPD Quality Improvement Committee. She is also a member of several medical organizations, including the American Thoracic Society and the European Respiratory Society. She serves as an associate editor for the journal Thorax and serves on the editorial board for the Journal of the COPD Foundation. She also serves on the scientific advisory committees for the COPD Foundation, American Thoracic Society and American Lung Association as well as chairs the Educational Materials committee for the COPD Foundation.

George R. Washko, MD, MMSc

George Washko is an Associate Professor of Medicine at Harvard Medical School and staff pulmonologist at Brigham and Women’s Hospital. He completed his medical school training at Georgetown University, medical residency at Beth Israel Deaconess Medical Center, and then fellowship training in the Harvard Combined Pulmonary and Critical Care Program. Dr. Washko has been on staff in the Pulmonary Division at Brigham and Women’s Hospital since 2006 where his clinical responsibilities have included attending in the Thoracic Surgery Intensive Care Unit as well as the outpatient evaluation of patients for lung transplantation. He is also a clinical investigator and has been active in several local, national, and international therapeutic trials. His current focus is on quantitative image analysis and the application of such tools to clinical care and investigation. He holds multiple R01 awards in this area in addition to contracts to process scans from local, national and international investigations such as the Framingham Heart Study and an ongoing investigation of the effects of occupational exposure on lung function in China.